Porto, Portugal, October 6 2026
Smith+Nephew has announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant, expanding access to an innovative technology designed to address cartilage and osteochondral defects of the knee. The implant is being introduced across multiple European markets and will be featured at the International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit in Porto, Portugal, from October 8–10. The launch marks an important expansion of Smith+Nephew’s orthopedic and sports medicine portfolio, with the company positioning CARTIHEAL AGILI-C as an evidence-backed option for patients who may previously have had limited access to cartilage repair procedures. The implant is made from aragonite, a naturally occurring form of calcium carbonate, which functions as a biphasic scaffold intended to support cartilage repair, bone restoration, and pain relief.
CARTIHEAL AGILI-C Expands European Cartilage Repair Options
The CARTIHEAL AGILI-C Implant is designed to support the treatment of cartilage and osteochondral defects while addressing several challenges associated with joint preservation. Its aragonite-based structure acts as a biphasic scaffold, providing a framework intended to support tissue repair within the treated area. Smith+Nephew introduced the technology in the United States in 2024 and is now expanding its commercial availability across Europe. The initial European launch includes Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Switzerland, and the United Kingdom, with additional countries expected to follow. The broader availability of the implant could provide orthopedic surgeons with another option for patients requiring cartilage repair, particularly in cases where conventional approaches may not adequately address the underlying cartilage and bone defects.
Five-Year Clinical Data Show Improved Outcomes
The European launch follows the publication of data from a multicenter, randomized controlled trial evaluating the CARTIHEAL AGILI-C Implant against surgical standard of care. According to the study findings cited by Smith+Nephew, patients treated with the implant demonstrated higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) compared with patients receiving debridement or microfracture through follow-up extending to 60 months. The reported results also included improvements in knee pain relief and quality of life, with patients receiving the implant showing superior outcomes over a five-year period. Improvements were additionally reported in functional activities involving daily living, sports, and recreation at two, four, and five years. The company also reported that no statistically significant difference in clinical outcomes was observed between patients with and without osteoarthritis who received the implant, based on the cited follow-up analysis. These findings add clinical evidence supporting the use of the technology for cartilage repair and joint preservation.
Advertisement
Smith+Nephew Advances Orthopedic Sports Medicine
The CARTIHEAL launch reinforces Smith+Nephew’s focus on orthopedic innovation, sports medicine, and tissue repair technologies. Cartilage and osteochondral defects remain challenging conditions in orthopedic care because damaged cartilage has limited natural regenerative capacity. By combining a structural scaffold with an approach intended to support cartilage and bone repair, the CARTIHEAL AGILI-C technology is aimed at expanding treatment options for eligible patients. The technology will be highlighted at the ICRS Summit in Portugal, providing an opportunity for orthopedic specialists to review clinical evidence, surgical applications, and developments in cartilage regeneration and joint preservation. Smith+Nephew said expanding access to the implant is part of its broader commitment to addressing unmet clinical needs and improving long-term patient outcomes. The European commercialization of CARTIHEAL AGILI-C represents another step in the development of advanced medical technologies intended to help patients manage joint damage, improve function, reduce pain, and potentially return to active lifestyles. As the implant becomes available across additional European markets, continued clinical experience and scientific exchange are expected to contribute to understanding its role in modern cartilage repair and orthopedic sports medicine.
Source: Smith+Nephew press release
